国产日韩高清中文无码av,久久91热狠狠色精品一区,亚洲啪AV永久无码精品放毛片,99热这里只有是精品2

原文鏈接：https://doi.org/10.1016/j.jpba.2021.114347

Abstract

　　Weikangling capsules (WKLCs), a Chinese patent medicine consisting of 8 Chinese drugs, have been widely used in clinic to treat gastrointestinal diseases for more than 30 years. The current “Chinese Pharmacopoeia” (2020 Edition, ChP2020) uses paeoniflorin content (≥ 1.0 mg per capsule) as the standard of quality control, but it is insufficient to evaluate the overall quality of WKLCs. An efficient and economic method for quality control is urgently needed to ensure the quality consistency and clinical effects of WKLCs. Herein, a systematic and reliable method for the rapid analysis of chemical components in WKLCs was established for the first time based on ultra-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS). A total of 115 components covering 7 herbs in WKLCs were preliminarily identified by comparison with standard substances or literature. To evaluate the quality of 26 batches of WKLCs, a new method of fingerprinting combined with quantitative analysis was established, and 16 common peaks were selected to establish the fingerprint similarity model (similarity>0.90). Simultaneously, the contents of albiflorin, paeoniflorin, dactylorhin A, militarine, and glycyrrhizic acid were determined to be 0.82 ± 0.22, 2.09 ± 0.24, 1.15 ± 0.40, 3.73 ± 0.76 and 0.99 ± 0.20 mg/capsule, respectively. The transfer rates and dissolution curves of the five compounds were successfully detected in WKLCs, and the average transfer rates were 67.2%, 33.0%, 68.3%, 54.7%, and 33.7%, respectively. Notably, the dissolution profiles of different manufacturers presented remarkable differences in pH 1.2 hydrochloric acid solution. This method not only qualitatively identified the chemical components of Chinese patent medicines at the microlevel but also evaluated the quality consistency between batches at the macrolevel, which provided a comprehensive reference for the quality consistency of Chinese patent medicines between batches.

…………

2. Materials and methods 

2.1. Chemicals and materials

…… The detailed information of all samples is  listed in Table S1. The standard substances, including liquiritin,  isoliquiritin, liquiritin apioside, isoliquiritin apioside, ononin, gly-cyrrhizic acid, glycyrrhetinic acid, paeoniflorin, albiflorin, oxypaeo-niflorin, benzoylpaeoniflorin, militarine, corydaline,  tetrahydropalmatine, protopine, ginsenoside Rg1, ginsenoside Rb1,  and ginsenoside Re were purchased from Chengdu Desite Biological  Technology Co., Ltd. (Sichuan, China);

…………